Immunoliposomes for the targeted delivery of antitumor drugs

E Mastrobattista, GA Koning, G Storm*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

144 Citations (Scopus)

Abstract

This review presents an overview of the field of immunoliposome-mediated targeting of anticancer agents. First, problems that are encountered when immunoliposomes are used for systemic anticancer drug delivery and potential solutions are discussed. Second, an update is given of the in vivo results obtained with immunoliposomes in tumor models. Finally, new developments on the utilization of immunoliposomes for the treatment of cancer are highlighted. (C) 1999 Elsevier Science B.V. All rights reserved.

Original languageEnglish
Pages (from-to)103-127
Number of pages25
JournalAdvanced Drug Delivery Reviews
Volume40
Issue number1-2
Publication statusPublished - 10-Nov-1999

Keywords

  • anticancer agents
  • immunoliposomes
  • PH-SENSITIVE IMMUNOLIPOSOMES
  • STERICALLY STABILIZED LIPOSOMES
  • ANTIBODY-DIRECTED LIPOSOMES
  • ENDOTHELIAL GROWTH-FACTOR
  • IN-VIVO
  • CANCER-THERAPY
  • SOLID TUMORS
  • POLY(ETHYLENE GLYCOL)
  • STEALTH LIPOSOMES
  • CIRCULATION TIME

Cite this